Bupivacaine 0.125% — Competitive Intelligence Brief

Bupivacaine 0.125% (Bupivacaine 0.125%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

Bupivacaine 0.125% (Bupivacaine 0.125%) — Shanghai Pulmonary Hospital, Shanghai, China. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine 0.125% TARGET	Bupivacaine 0.125%	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Local anesthetic	Voltage-gated sodium channels
zonisamide high dose group	zonisamide high dose group	Eisai Korea Inc.	marketed	Sulfonamide anticonvulsant	Voltage-gated sodium channels, T-type calcium channels, GABA enhancement
Lamictal TM	Lamictal TM	Central Mental Clinic for Outpatients of Baku City	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Scalp block with 0.5% plain Marcaine	Scalp block with 0.5% plain Marcaine	Chiang Mai University	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Adjunctive Zonisamide	Adjunctive Zonisamide	Eisai Inc.	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Ropivacaine/Fentanyl	Ropivacaine/Fentanyl	National Institute for Tuberculosis and Lung Diseases, Poland	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu opioid receptor (fentanyl)
Perineural Dexamethasone and bupivacaine	Perineural Dexamethasone and bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Local anesthetic with adjuvant corticosteroid	Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class